Previous 10 | Next 10 |
Image source: The Motley Fool. G1 Therapeutics, Inc. (NASDAQ: GTHX) Q4 2019 Earnings Call Feb 26, 2020 , 4:30 p.m. ET Operator Continue reading
G1 Therapeutics, Inc. (GTHX) Q4 2019 Earnings Conference Call February 26, 2020 4:30 PM ET Company Participants Jeff Macdonald - Senior Director of Investor Relations Mark Velleca - Chief Executive Officer Raj Malik - Chief Medical Officer & Senior Vice President, R&D J...
G1 Therapeutics (NASDAQ: GTHX ): Q4 GAAP EPS of -$0.94 beats by $0.02 . More news on: G1 Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
New Drug Application (NDA) submission for trilaciclib in small cell lung cancer on track for 2Q20 Trilaciclib selected for inclusion in I-SPY 2 breast cancer trial Rintodestrant (G1T48) combination trial with palbociclib expected to initiate in 2Q20 Management to host webcast and con...
RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that the company will present corporate updates at the following investor conferences in March 2020: Cowen & Company 40 th An...
RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that it will host a webcast and conference call to provide a corporate and financial update for the fourth quarter and full year of 20...
RESEARCH TRIANGLE PARK, N.C., Feb. 17, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that Chief Medical Officer Raj Malik, M.D., will participate in the “Breast Cancer – The Moving Landscape” panel ...
RESEARCH TRIANGLE PARK, N.C., Feb. 06, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will participate in a fireside chat at the Guggenheim Healthcare Talks: Oncolog...
SAN FRANCISCO and RESEARCH TRIANGLE PARK, N.C., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Quantum Leap Healthcare Collaborative™ (QLHC) and G1 Therapeutics, Inc. (Nasdaq: GTHX ) announced today a collaboration to evaluate trilaciclib, an investigational therapy designed to improve outcome...
RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will present a company overview at the 38 th Annual J.P. Morgan Healthcare Con...
News, Short Squeeze, Breakout and More Instantly...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
- Achieved $14.1 Million in Net Revenue from Sales of COSELA® (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That Updated Efficacy Results from Phase 2 Trial of Trilaciclib in Combination with a TROP2 Antibod...
RESEARCH TRIANGLE PARK, N.C. and BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, and Pepper Bio, the world’s first transomics drug discovery and development company, announced a global licensing agreement (excluding t...